Armis Advisers LLC purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 965 shares of the medical research company's stock, valued at approximately $251,000.
A number of other hedge funds have also made changes to their positions in AMGN. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at approximately $25,000. Pinney & Scofield Inc. acquired a new stake in Amgen in the fourth quarter valued at approximately $26,000. Ritter Daniher Financial Advisory LLC DE grew its position in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after acquiring an additional 51 shares in the last quarter. Synergy Investment Management LLC acquired a new position in shares of Amgen during the 4th quarter worth $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen during the 4th quarter valued at $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on the stock. Wells Fargo & Company reiterated an "equal weight" rating on shares of Amgen in a report on Wednesday, February 5th. Johnson Rice set a $294.00 price objective on Amgen in a research note on Wednesday, March 5th. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Piper Sandler dropped their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. Finally, Guggenheim assumed coverage on shares of Amgen in a report on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective for the company. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Amgen currently has an average rating of "Hold" and a consensus target price of $309.22.
Read Our Latest Stock Report on Amgen
Amgen Price Performance
AMGN stock traded up $4.64 during trading on Friday, hitting $288.18. The company had a trading volume of 5,372,667 shares, compared to its average volume of 2,813,147. The company has a fifty day moving average price of $283.86 and a two-hundred day moving average price of $285.50. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The company has a market cap of $154.96 billion, a P/E ratio of 38.17, a P/E/G ratio of 2.63 and a beta of 0.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The company had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the previous year, the company earned $3.96 EPS. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. Equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.
Amgen Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.30%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's payout ratio is currently 86.86%.
About Amgen
(
Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
